Tonix Pharmaceuticals Holding news

The company secured a second major commercial payer agreement, significantly expanding market access for its flagship product TONMYA. The achievement of 52 million lives in commercial coverage (29% of total) represents substantial progress in the early commercialization phase. TONMYA's status as the first new fibromyalgia treatment in 15+ years and broad Medicaid coverage (~75 million lives) demonstrates strong market positioning and execution on commercial objectives.

The company achieved FDA approval and successful commercial launch of TONMYA, the first new fibromyalgia treatment in 15+ years. Q1 2026 results show strong early adoption with nearly 2,150 prescribing providers and over 5,400 prescriptions filled. The company is presenting real-world evidence at a major health economics conference and has patent protection extending to 2034/2035, indicating strong market positioning and growth trajectory.

The company achieved FDA approval for TONMYA as the first new fibromyalgia treatment in 15+ years, successfully commercialized it, and published peer-reviewed pharmacokinetic data supporting its efficacy and safety profile. The sublingual formulation demonstrated superior bioavailability and favorable tolerability, with patent protection extending to 2034/2035. These milestones represent significant commercial and clinical validation.

The company is actively presenting at major industry conferences, has successfully launched TONMYA® with strong early adoption (1,500+ prescriptions in 3+ months), maintains a diversified pipeline with multiple candidates in clinical development, and continues to expand its commercial infrastructure. These indicators suggest operational momentum and investor confidence.

Listed as a sponsor of the event, showing support for Lyme disease research initiatives but no specific business developments or product announcements mentioned.